Business Wire

IPCom launches Consulting Services; announces R&D department

Share

IPCom, an Intellectual Property (IP) management and patent licensing company supported by pioneering R&D capabilities, has announced the launch of new and restructured service divisions for the telecoms and technology sectors.

IPCom's new IP Consulting Services will provide SMEs and start-ups with the consulting and practical support needed to develop, patent and monetize new technologies. The comprehensive offering will include IP assessment, due diligence, documentation and assertion. The company has also announced its R&D department, headed up by Martin Hans, Head of Research and Standardization/Development at IPCom.

The moves support IPCom's ongoing efforts to re-balance the power between patent licensees and licensors, shining a light on unfair, anti-competitive practices, and promoting an industry-wide commitment to FRAND (fair, reasonable and non-discriminatory) principles.

Activities will be supported by an R&D team of scientists and engineers dedicated to innovation in the mobile communications sector, and the development and rollout of the new mobile connectivity standard, 5G. Martin Hans is a prolific inventor who has developed together with his current team more than 500 patent families, including more than 50 Standard Essential Patents in GSM, UMTS and LTE communications standards. Hans will continue to oversee IPCom's active contribution to industry bodies focussing on 3GPP, the body currently developing the next generation (5G) of communication standards.

“Now is the perfect time to showcase over two decades’ of IPCom's R&D work, and to roll out new services which will help ensure that credit is given to even the smallest companies and innovators behind the big ideas,” said Pio Suh, Managing Director, IPCom. “For too long, mega telecoms companies have monopolised the industry, overpowering smaller companies and making it difficult for them to license and get credit for their innovations. However, I’m confident we can turn this on its head.

“Access to ideas shouldn’t be dependent on might and capital, and I’m looking forward to developing IPCom's new services, overseeing licensing activity on FRAND terms, and empowering companies to fairly and transparently monetize their ideas,” Suh finished.

Part of IPCom's management team of business leaders, IP experts, legal practitioners, and telecommunications engineers, Suh works alongside Bernhard Frohwitter, co-founder; Christoph A. Schoeller, co-founder; and Martin Hans, Head of Research and Standardization/Development. Suh will support IPCom's corporate expansion, including a number of key upcoming additions to its team.

-ENDS-

About IPCom

IPCom GmbH & Co. KG is an intellectual property (IP) rights licensing and technology R&D company, which supports companies with asserting patent rights and concluding patent license agreements on FRAND (fair, reasonable, and non-discriminatory) terms. IPCom holds over 200 patent families in the field of mobile communications, with more than 1,000 patents registered in Europe, the US and Asia, most of which have been granted. Committed to the principles of FRAND, fair play and competitive advantage, IPCom also offers consulting services to companies in the telecoms space, with the aim of levelling the playing field and ensuring those behind the development of standard essential patents (SEPs) are fairly rewarded for their technologies and work.

IPCom is headquartered in Pullach, Munich, Germany, and operates on a global basis.

http://www.ipcom-munich.com

Contact information

IPCom
Media contacts:
Paul Campbell
Babel PR
Tel: +44 (0)20 7434 5552
Email: paul@babelpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 20:59:00 EESTPress release

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who

Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 16:05:00 EESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 15:30:00 EESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include

Schlumberger Announces Second-Quarter 2019 Results19.7.2019 14:00:00 EESTPress release

Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente

Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 13:46:00 EESTPress release

Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe

Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 13:00:00 EESTPress release

Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail fluke-info@fluke.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom